Other active comparator
Macupatide
OTHER_ACTIVE_macupatide
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.46 (0.00 to 20.74) | 0.62 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.48 (0.00 to 21.07) | 0.64 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.46 (0.01 to 17.39) | 0.70 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.44 (0.01 to 17.39) | 0.69 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.90 (0.06 to 5.71) | 0.74 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.85 (0.06 to 5.71) | 0.63 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.60 (0.10 to 13.27) | 0.61 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.57 (0.09 to 14.11) | 0.54 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.52 (0.62 to 9.41) | 0.34 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.45 (0.56 to 9.27) | 0.30 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.18 (0.00 to 3.12) | 0.85 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.18 (0.00 to 2.91) | 0.83 |